Showing 1121-1130 of 10032 results for "".
Advances in Topical Acne Therapy
https://practicaldermatology.com/topics/practice-management/advancesin-topical-acne-therapy/21020/Even severe acne patients can be safely—and effectively—treated with topicals today.Advocacy Groups and Physicians: The New Power Couple
https://practicaldermatology.com/topics/practice-management/advocacy-groups-and-physicians-the-new-power-couple/21191/Patient advocacy organizations partnering with dermatology physician-scientists offer an exciting new model for optimized patient care.Therapeutics Update: Notable Approvals in 2017
https://practicaldermatology.com/topics/skin-cancer-photoprotection/therapeutics-update-notable-approvals-in-2017/20398/A look at the newest additions to the medicine chest.Topical Corticosteroids and Topical Calcineurin Inhibitors in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/topical-corticosteroids-and-topical-calcineurin-inhibitors-atopic-dermatitis/29118/Analysis of a 2024 study by Gether et al., in which the authors compared the effectiveness of topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) in adults with atopic dermatitis (AD).Monoclonal Antibodies for Restoring a Healthy Skin Microbiome in Atopic Dermatitis Patients
https://practicaldermatology.com/topics/research-update/monoclonal-antibodies-restoring-healthy-skin-microbiome-atopic-dermatitis-patients/24566/Monoclonal Antibodies for Restoring a Healthy Skin Microbiome in Atopic Dermatitis PatientsA Growing Neuromodulator Market: Daxxify Approved
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/a-growing-neuromodualtor-market-daxxify-approved/23797/Revance Therapeutics’ DaxibotulinumtoxinA-lanm is now approved to treat glabellar lines.10 Things Dermatologists Need to Know About Treating Vitiligo Today
https://practicaldermatology.com/topics/pigmentary-disorders/10-things-dermatologists-need-to-know-about-treating-vitiligo-today/22988/New and emerging treatment approaches offer hope for this challenging condition.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muStaphylococcus aureus Colonization
https://practicaldermatology.com/issues/september-2025/staphylococcus-aureus-colonization/37626/In a recent review article, Piewngam and Otto examined the epidemiology, mechanisms, and clinical implications of Staphylococcus aureus (S. aureus) colonization, while evaluating both current and emerging strategies for decolonization.Treating Severe Acne in Transgender Patients: An Update
https://practicaldermatology.com/columns/clinical-focus-1/treating-severe-acne-in-transgender-patients-an-update/23472/Understanding the implications of isotretinoin use in FTM acne patients.